Apremilast

CAS 608141-41-9 27 current records 1 historicalSmall Molecule

Who holds supplier records for Apremilast? 27 organisations hold a current record for Apremilast: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: India (17), China (4), Spain (1), Slovenia (1) and 2 other countries (2); not recorded for 2.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Apremilast: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/apremilast

Reading the evidence

  • 27 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    17 of the 25 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 17 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Apremilast expires 27 May 2042. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (27)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Apremilast. Country is the organisation's recorded country, not necessarily the manufacturing site.

India17China4Spain1Slovenia1Taiwan1Poland1Country not recorded for 2
Need Apremilast sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (1)

Organisations whose Type II DMFs for Apremilast are no longer active. These show a past filing, not current supply.

Show all 1 historical record

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (19 listed products contain Apremilast). The latest listed patent expires 27 May 2042. The latest listed exclusivity runs to 25 Oct 2027. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Apremilast is an oral small molecule inhibitor of the enzyme phosphodiesterase 4 (PDE4), which is used for the treatment of certain types of psoriasis and psoriatic arthritis. By inhibiting PDE4, apremilast reduces inflammation by increasing intracellular cAMP levels.

Chemical identity

IUPAC name
N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide
Canonical SMILES
CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC
InChIKey
IMOZEMNVLZVGJZ-QGZVFWFLSA-N
Synonyms
Otezla API, cc-10004, cc10004, otezla

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Phosphodiesterase 4 Inhibitor
Mechanism of action
Phosphodiesterase 4 Inhibitors

Therapeutic areas

DermatologyRheumatology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Apremilast?

27 organisations hold an active US FDA Type II Drug Master File or a CEP for Apremilast: MSN LIFE SCIENCES PRIVATE LIMITED (India), Alembic Pharmaceuticals Limited (India), Dr. Reddy's Laboratories Ltd. (India), LUPIN MANUFACTURING SOLUTIONS LTD, QUIMICA SINTETICA SA (Spain), ALIVUS LIFE SCIENCES LTD (India), Alkem Laboratories Limited (India) and ANHUI POLY PHARM CO LTD (China), and 19 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Apremilast Drug Master Files are active?

MSN LIFE SCIENCES PRIVATE LIMITED (DMF 30866, 31159), Alembic Pharmaceuticals Limited (DMF 32177, 33655), Dr. Reddy's Laboratories Ltd. (DMF 31356, 30732), LUPIN MANUFACTURING SOLUTIONS LTD (DMF 30248, 31266), QUIMICA SINTETICA SA (DMF 34915, 32119), ALIVUS LIFE SCIENCES LTD (DMF 31490), Alkem Laboratories Limited (DMF 32114) and ANHUI POLY PHARM CO LTD (DMF 38437) and 19 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Apremilast records mean?

1 organisation has only inactive Type II DMFs for Apremilast. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does the FDA Orange Book list patents for products containing Apremilast?

Yes. The latest patent listed for an approved US product containing Apremilast expires 27 May 2042, across 19 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Apremilast supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Apremilast?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.